This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

II. Two-Year Relapse Rates

Gerard E. Hogarty, MSW; Solomon C. Goldberg, PhD; Nina R. Schooler, PhD; Richard F. Ulrich; the Collaborative Study Group

Arch Gen Psychiatry. 1974;31(5):603-608.

Abstract
We examined the effects of maintenance chlorpromazine and major role therapy (MRT) in forestalling the relapse of 374 schizophrenic patients recently discharged from the hospital.

Chlorpromazine is significantly more effective than placebo in forestalling relapses (p<.001). By 24 months, 80% of placebo-treated patients have relapsed compared to 48% of those drug-treated. Further, although drug therapy is more effective than placebo in both sexes, the size of the difference is significantly greater for women than men (p<.01). There is no sex difference with placebo treatment.

There is no significant effect of MRT during the entire treatment period. However, MRT does reduce relapses among those who survive in the community for six months after hospital discharge. These results were replicated at three clinics.

Author Affiliations
From the Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine (Messrs. Hogarty and Ulrich); the Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Md (Drs. Goldberg and Schooler); and the Friends' Medical Science Research Center, Inc, Baltimore (the Collaborative Study Group).

Footnotes
Accepted for publication July 18, 1974.

Reprint requests to 3811 O'Hara St, Pittsburgh, PA 15261 (Mr. Hogarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT | FULL TEXT  

Minimal-medication approaches to treating schizophrenia
Calton and Spandler
Adv. Psychiatr. Treat. 2009;15:209-217.
ABSTRACT | FULL TEXT  

Psychosocial Treatments to Promote Functional Recovery in Schizophrenia
Kern et al.
Schizophr Bull 2009;35:347-361.
ABSTRACT | FULL TEXT  

A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia
Calton et al.
Schizophr Bull 2008;34:181-192.
ABSTRACT | FULL TEXT  

Gerard E. Hogarty (1935 2006): Combining Science and Humanism to Improve the Care of Persons With Schizophrenia
Eack et al.
Schizophr Bull 2007;33:1056-1062.
ABSTRACT | FULL TEXT  

Forty-five years of schizophrenia: personal reflections.
Seeman
History of Psychiatry 2006;17:363-373.
ABSTRACT  

Do Patients with Schizophrenia Ever Show Periods of Recovery? A 15-Year Multi-Follow-up Study
Harrow et al.
Schizophr Bull 2005;31:723-734.
ABSTRACT | FULL TEXT  

Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior
Hogarty et al.
Arch Gen Psychiatry 2004;61:866-876.
ABSTRACT | FULL TEXT  

Evaluating the Effectiveness of Cognitive-Behavioral Treatment of Residual Symptoms and Impairment in Schizophrenia
Bradshaw and Roseborough
Research on Social Work Practice 2004;14:112-120.
ABSTRACT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Focus 2004;2:146-157.
ABSTRACT | FULL TEXT  

Schizophrenia
Freedman
NEJM 2003;349:1738-1749.
FULL TEXT  

Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?
Rosenheck et al.
Arch Gen Psychiatry 1998;55:618-625.
ABSTRACT | FULL TEXT  

Gender and Attitudes Towards People With Schizophrenia. Results of a Representative Survey in the Federal Republic of Germany
Angermeyer et al.
Int J Soc Psychiatry 1998;44:107-116.
ABSTRACT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Am. J. Psychiatry 1997;154:1504-1513.
ABSTRACT | FULL TEXT  

Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, II: Effects on Adjustment of Patients
Hogarty et al.
Am. J. Psychiatry 1997;154:1514-1524.
ABSTRACT | FULL TEXT  

Does Quality of Life Differ in Schizophrenic Women and Men? An Empirical Study
Roder-Wanner et al.
Int J Soc Psychiatry 1997;43:129-143.
ABSTRACT  

Clinical Risk Following Abrupt and Gradual Withdrawal of Maintenance Neuroleptic Treatment
Viguera et al.
Arch Gen Psychiatry 1997;54:49-55.
ABSTRACT  

Intermittent vs Maintenance Medication in Schizophrenia: Two-Year Results
Herz et al.
Arch Gen Psychiatry 1991;48:333-339.
ABSTRACT  

Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia: II. Two-Year Effects of a Controlled Study on Relapse and Adjustment
Hogarty et al.
Arch Gen Psychiatry 1991;48:340-347.
ABSTRACT  

Posthospital Course and Outcome in Schizophrenia
Carone et al.
Arch Gen Psychiatry 1991;48:247-253.
ABSTRACT  

Family Interventions for Schizophrenia
Tarrier and Barrowclough
Behav Modif 1990;14:408-440.
ABSTRACT  

Inpatient Family Intervention: A Randomized Clinical Trial: II. Results at Hospital Discharge
Haas et al.
Arch Gen Psychiatry 1988;45:217-224.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Prediction of Relapse in Schizophrenia
Lieberman et al.
Arch Gen Psychiatry 1987;44:597-603.
ABSTRACT  

Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder et al.
Arch Gen Psychiatry 1987;44:518-521.
ABSTRACT  

Borderline and Schizotypal Personality Disorders Treated With Low-Dose Thiothixene vs Placebo
Goldberg et al.
Arch Gen Psychiatry 1986;43:680-686.
ABSTRACT  

Family Management in the Prevention of Morbidity of Schizophrenia: Clinical Outcome of a Two-Year Longitudinal Study
Falloon et al.
Arch Gen Psychiatry 1985;42:887-896.
ABSTRACT  

The Chestnut Lodge Follow-up Study: I. Follow-up Methodology and Study Sample
McGlashan
Arch Gen Psychiatry 1984;41:573-585.
ABSTRACT  

Reliability of Norepinephrine and Major Monoamine Metabolite Measurements in CSF of Schizophrenic Patients
Linnoila et al.
Arch Gen Psychiatry 1983;40:1290-1294.
ABSTRACT  

Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT  

Personality Determinants of Leadership and Participation in a Sociotherapy Program
Smith and Fromm
Human Relations 1982;35:433-448.
ABSTRACT  

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane et al.
Arch Gen Psychiatry 1982;39:70-73.
ABSTRACT  

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride
Hogarty et al.
Arch Gen Psychiatry 1979;36:1283-1294.
ABSTRACT  

Day Treatment and Psychotropic Drugs in the Aftercare of Schizophrenic Patients: A Veterans Administration Cooperative Study
Linn et al.
Arch Gen Psychiatry 1979;36:1055-1066.
ABSTRACT  

Drug and Family Therapy in the Aftercare of Acute Schizophrenics
Goldstein et al.
Arch Gen Psychiatry 1978;35:1169-1177.
ABSTRACT  

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics
Quitkin et al.
Arch Gen Psychiatry 1978;35:889-892.
ABSTRACT  

Controlled Evaluation of a Hospital-Originated Community Transitional System
Kuldau and Dirks
Arch Gen Psychiatry 1977;34:1331-1340.
ABSTRACT  

The Aftercare Clinic as a Residency Training Site: 'Community Neuropsychiatry'
Miller
Arch Gen Psychiatry 1977;34:1349-1352.
ABSTRACT  

Fluphenazine Decanoate, Oral Fluphenazine, and Placebo in Treatment of Remitted Schizophrenics: II. Rating Scale Data
Rifkin et al.
Arch Gen Psychiatry 1977;34:1215-1219.
ABSTRACT  

Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients
Hogarty and Ulrich
Arch Gen Psychiatry 1977;34:297-301.
ABSTRACT  

Prediction of Relapse in Schizophrenic Outpatients Treated by Drug and Sociotherapy
Goldberg et al.
Arch Gen Psychiatry 1977;34:171-184.
ABSTRACT  

Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally, and Placebo in Remitted Schizophrenics: I. Relapse Rates After One Year
Rifkin et al.
Arch Gen Psychiatry 1977;34:43-47.
ABSTRACT